Definium Therapeutics Engages Investors with Upcoming Conference Participation

Definium Therapeutics, Inc. (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company dedicated to developing innovative therapeutics targeting the root causes of psychiatric and neurological disorders, has announced an exciting schedule of participation in several investor conferences and events throughout April and May 2026. This engagement reflects the company's commitment to transparency and open communication with its investors and the broader healthcare community.

Definium will kick off its conference appearances with a fireside chat at the 25th Annual Needham Virtual Healthcare Conference. Scheduled for Thursday, April 16, 2026, at 3:00 PM EDT, this virtual event aims to provide investors with insights into the company's strategic direction and the potential impact of its therapeutic innovations. Interested parties can access the conference via the provided webcast link.

Following the Needham conference, Definium will host its Investor & Analyst Day on Wednesday, April 22, 2026, from 10:00 AM to 12:00 PM EDT at Well& by Durst, located in New York City. This in-person event is exclusive to invited research analysts and institutional investors, giving attendees a unique opportunity to engage directly with the company's management team. After the formal presentations, a lunch will be provided, fostering further discussion and networking among attendees.

On Monday, April 27, 2026, Definium will participate in the Needham Virtual Psychedelics Forum, featuring a panel discussion titled "Clinical Risk, Regulatory Reality and the Path to Scale." Scheduled for 11:00 AM EDT, this panel will delve into the complexities surrounding psychedelic therapeutics, including clinical and regulatory challenges. Access to this presentation will be coordinated through Needham representatives.

Finally, Definium will present at the 2026 RBC Capital Markets Global Healthcare Conference on Tuesday, May 19, 2026, at 8:00 AM EDT in New York, NY. This event will further solidify the company's presence in the healthcare investment landscape, allowing them to showcase their advancements in therapeutic development.

Definium has made it a priority to ensure all interested stakeholders can access its content. Audio webcasts and replays of all presentations will be available on the company's Investor Relations website for up to 90 days following each event, ensuring that both current and potential investors can stay informed.

Definium Therapeutics is on a mission to revolutionize mental health care by applying scientific rigor to the development of psychedelic-based therapies. The company seeks to create accessible treatment options that address the underlying causes of psychiatric and neurological disorders. By transforming evidence into impactful solutions, Definium aims to tackle the growing mental health crisis head-on, paving the way for a healthier future.

Headquartered in New York, Definium Therapeutics trades on Nasdaq under the ticker symbol DFTX. For additional information, interested parties can visit their website and follow them on social media platforms such as Instagram, LinkedIn, and X.

With a robust schedule of upcoming events, Definium Therapeutics is poised to engage with investors and share its vision for the future of psychiatric care. The company’s dedication to transparency and innovation in therapeutic development highlights its potential to make a significant impact in the healthcare industry.